Trial
NCT00775606
Immune Reconstitution of Lopinavir/Ritonavir-Based vs Efavirenz-based HAART in Advanced HIV Disease
Phase IVTERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Rush University Medical Center
Collaborators
University of Chicago; University of Illinois at Chicago; Ruth M. Rothstein CORE Center; Abbott; Gilead Sciences
Condition
Acquired Immune Deficiency Syndrome
Intervention
Lopinavir 400 mg/ritonavir 100 mg
Why stopped
Study stopped 12/2010 due to poor enrollment. Only 15 of 60 needed enrolled.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-05-26